New asthma shot aims to cut attacks in half
NCT ID NCT07342803
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called LP-003 in 200 adults with moderate to severe allergic asthma. The goal is to see if it reduces asthma attacks and improves breathing compared to a placebo or an active drug. Participants receive injections and are monitored for about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Allergy shots may unlock better asthma control by targeting hidden immune signals
- New asthma drug JYB1904 shows promise in early trial
- Cleveland clinic launches asthma research to develop better tests and treatments
- Skin test may personalize asthma care for kids
- Cat allergy treatment gets a needle upgrade: fewer shots, same hope
- Biosimilar switch for asthma and hives under Real-World study